ASND
BUY
Conviction: 4/5
$9B
Ascendis Pharma
Current: $145
Investment Thesis
Two profitable quarters achieved. Yorvipath 2025 revenue €477M crushing expectations. CNP PDUFA Feb 28, 2026 (imminent). Vision 2030 targets €5B+ revenue. TransCon platform now proven commercially.
Bull Case
Yorvipath trajectory extraordinary (€477M in year 1). CNP approval Feb 28 adds third product. Profitable and cash-generative. €500M operating cash flow guided for 2026. $120M buyback announced.
Bear Case
CNP faces entrenched Voxzogo competition. Valuation rich if CNP disappoints. EUR reporting creates FX volatility for USD investors.
Drug Portfolio (4)
Rare Disease
TransCon prodrug
SC
Rare Disease
TransCon prodrug
SC
Rare Disease
TransCon prodrug
SC
| Drug | Stage | Role | Ownership | Area | Modality |
|---|
| TransCon IL-2 | PHASE1 | ORIGINATOR | 100% | Oncology | TransCon prodrug |
Financials (USD)
| Period | Revenue ($M) | Gross Margin | R&D | SG&A | Op Income | Op Margin | Net Income | EPS |
|---|
| 2023A | $430 | 84.9% | $215 | $280 | $-130 | -30.2% | $-115 | $-2.05 |
| 2024A | $680 | 85.0% | $340 | $320 | $-82 | -12.1% | $-57 | $-0.98 |
| 2025A | $950 | 84.9% | $475 | $350 | $-18 | -1.9% | $10 | $0.17 |
| 2026E | $1,250 | 85.0% | $500 | $400 | $162 | 13.0% | $140 | $2.25 |
| 2027E | $1,600 | 85.0% | $560 | $450 | $350 | 21.9% | $300 | $4.75 |
| 2028E | $1,950 | 85.0% | $600 | $500 | $557 | 28.6% | $480 | $7.50 |
Recent Quarters
| Quarter | Revenue ($M) | Gross Margin | Op Margin | EPS |
|---|
| Q4 2026E | $335 | 85.1% | 15.2% | $0.69 |
| Q4 2025 | $264 | 84.8% | -0.4% | $0.17 |
| Q4 2024 | $200 | 85.0% | -2.5% | $0.03 |
| Q3 2026E | $325 | 84.9% | 14.8% | $0.68 |
| Q3 2025 | $248 | 85.1% | 1.2% | $0.13 |
| Q3 2024 | $175 | 85.1% | -12.0% | $-0.24 |
Catalysts (3)
ASND - FY 2025 Results
GUIDANCE
SM
investors.ascendispharma.com JPM 2026 Presentation
Mid-Feb 2026
TransCon CNP - Achondroplasia - FDA PDUFA
REGULATORY
SM
investors.ascendispharma.com PDUFA extension PR Nov 25, 2025
Feb 28, 2026
TransCon CNP - Achondroplasia - EMA Decision
REGULATORY
SM
investors.ascendispharma.com JPM 2026 Presentation
Q4 2026
Open Debates (4)
TransCon PTH Commercial Potential
Bull
Yorvipath €477M in 2025 proves HP market larger than bears feared. Management raised long-term target to €5B by 2030. Now profitable. CNP approval Feb 28 adds third leg.
Bear
Valuation stretched at ~$10B market cap with €720M revenue. CNP must deliver to justify multiple. Voxzogo has multi-year head start in achondroplasia.
Conviction: 4/5
TransCon CNP vs Voxzogo
Bull
Weekly dosing major compliance advantage in children. ApproaCH data clean, published in JAMA Pediatrics. FDA Priority Review suggests no major issues.
Bear
Voxzogo has 3+ year head start. Physicians may stick with known therapy. PDUFA extension raised some concerns.
Conviction: 3/5
Underappreciated Growth Driver: Yorvipath Launch Trajectory
Bull
Yorvipath achieved €477M in its first year — crushing every rare disease launch comp. This is a hypoparathyroidism drug with no approved competition until recently. The trajectory suggests peak sales well above the $1.5B consensus. The TransCon platform enables weekly dosing vs daily PTH for competitors, driving adherence in a chronic condition. Ascendis is now profitable and cash-flow positive — €500M OCF guided for 2026. The market still values ASND as a clinical-stage biotech.
Bear
Hypoparathyroidism is a small market (~200K patients globally). The launch pulled forward early adopters — growth will decelerate. Competition from Takeda's Natpara reintroduction or generics.
Conviction: 5/5
Underappreciated Risk: TransCon CNP vs Voxzogo Switching Dynamics
Bull
Weekly dosing (TransCon CNP) vs daily injection (Voxzogo) in pediatric patients — convenience advantage is enormous for children and parents. If efficacy is comparable, weekly wins.
Bear
Voxzogo has 3+ years of real-world data in achondroplasia. Parents are reluctant to switch a working treatment in their child. BioMarin is developing longer-acting Voxzogo formulations. Achondroplasia is a small market (~30K globally) and splitting it between two drugs limits both. TransCon CNP Phase 3 needs to show clear superiority, not just non-inferiority, to drive meaningful switching.
Conviction: 5/5
Data from Supabase · Updated 2026-03-24